NCT05875675View on ClinicalTrials.gov

Effects of Pioglitazone in Calcific Aortic Valve Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2028

Conditions
Calcification of Aortic ValveAortic Valve Stenosis
Interventions
DRUG

Drug: Pioglitazone Oral Tablet

Dietary Supplement: Pioglitazone 30 mg by mouth daily

DIETARY_SUPPLEMENT

Placebo

Dietary: Supplement: Placebo

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT05875675 - Effects of Pioglitazone in Calcific Aortic Valve Disease | Biotech Hunter | Biotech Hunter